| Document |
Document Title |
|
WO/2018/131593A1 |
This method for producing a nucleic acid array includes: a step (a) in which a layer (a PAG layer) of a resin composition including a photoacid generator (PAG) for generating an acid as a result of being exposed to light is formed on a s...
|
|
WO/2018/132673A1 |
This document provides methods and materials involved in identifying and/or treating acute GVHD. For example, methods and materials for detecting elevated levels of nucleic acid expression (e.g., an elevated level of MxA nucleic acid exp...
|
|
WO/2018/132720A1 |
This document provides materials and methods for making and using functional (e.g., vascularized) organ models (e.g., pancreas models). For example, functional pancreas models including an ECM containing a plurality (e.g., two or more) o...
|
|
WO/2018/131479A1 |
In order to evaluate the risk of a slope collapsing before installing a sensor, a risk determination device 100 comprises: a first calculation unit 110 that calculates a parameter to indicate the condition of soil on the basis of the rel...
|
|
WO/2018/131586A1 |
The present invention addresses the problem of providing: an anti-GPC3 antibody that recognizes an epitope different from those recognized by existing antibodies (e.g., GC33 and GC199), and that can specifically bind to GPC3 localized on...
|
|
WO/2018/132597A1 |
The present application provides constructs comprising an antibody moiety that specifically binds to a complex comprising a histone H3 peptide and an MHC class I protein. Also provided are methods of making and using these constructs.
|
|
WO/2018/132749A1 |
Provided herein are methods of determining resistance to checkpoint blockade (CPB) therapy in a cancer patient, methods of typing tumor cells of a cancer patient, methods of assigning treatment to a cancer patient and methods of treatmen...
|
|
WO/2018/131909A1 |
The present invention relates to: a pharmaceutical composition for preventing or treating brain-nervous system diseases, comprising as an active ingredient cord blood or a cord blood-derived cell which expresses or secretes PCNT; a compo...
|
|
WO/2018/129885A1 |
A detection kit for a whole blood C-reactive protein. The kit comprises a reagent R1 and a reagent R2, wherein the reagent R2 respectively sensitizes latex particles having different particle sizes by using C-reactive protein (CRP) antib...
|
|
WO/2018/132156A1 |
A system and method for monitoring the operating conditions of a steam turbine and developing an adaptive inspection interval (200) includes access to a digital data storage archive (210) containing information relating to use and operat...
|
|
WO/2018/132494A1 |
Disclosed herein are polynucleotides encoding ligand-inducible gene switch polypeptides, and systems comprising gene switch polypeptides for modulating the expression of a heterologous gene and an interleukin in a host cell. The composit...
|
|
WO/2018/130537A1 |
The present invention is directed to cell-protective, in particular, cardio- and renal-protective organic compounds, preferably to organic compounds that inhibit substrate phosphorylation by the G-protein-coupled receptor kinase 2 (GRK2,...
|
|
WO/2018/132838A2 |
IUI insemination (introduction of washed sperm into the uterus) should occur during a period of time when sperm Fc receptor (FcR) expression is going through a minimum, i.e., in a window of time about the minimum. In order to be ready to...
|
|
WO/2018/132287A1 |
The present invention is based on the identification of novel biomarkers predictive of responsiveness to anti-immune checkpoint therapies.
|
|
WO/2018/132383A1 |
Provided are agents that disrupt CRY1-CLOCK-BMAL1 ternary complexes. In certain aspects, the agents bind to the secondary pocket of CRY1 and inhibit interaction between the secondary pocket and the PAS-B domain of CLOCK, to disrupt CRY1-...
|
|
WO/2018/132702A1 |
The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relate...
|
|
WO/2018/130659A1 |
The invention relates to apolypeptide capable of binding to TGF-β for use in treating or preventing a condition associated with elevated or unwanted levels of TGF-β, wherein said polypeptide is capable of inhibiting theinteraction of T...
|
|
WO/2018/130555A1 |
The present invention relates to the field of neurodegenerative diseases. More specifically, the present invention relates to a screening assay to produce compounds stabilizing the gamma-secretase enzyme substrate complex, thereby increa...
|
|
WO/2018/131091A1 |
This image processing device 3 is provided with: a single-staining image calculation unit 361 for calculating, from a stained specimen image arrived at by imaging a specimen subjected to two or more types of staining, single-staining ima...
|
|
WO/2018/131192A1 |
A method of examining a subject's possibility of suffering from pancreatic cancer, said method being characterized by comprising measuring G-protein coupled receptor family C group 5 member C (GPRC5C) present in exosomes in a specimen co...
|
|
WO/2018/129625A1 |
A method of detecting a DSG2 autoantibody in a mammal is provided. The method includes contacting a biological sample obtained from a mammal with DSG2; and detecting the presence of DSG2 autoantibody bound to the DSG2 with a detectable a...
|
|
WO/2018/132753A1 |
Contemplated systems and methods verify a patient' s likely immune response to a neoepitope -based treatment by (a) assessing whether or not the patient's immune system is ready to mount an immune response, (b) determining prior response...
|
|
WO/2018/130871A1 |
A system, method, apparatus and diagnostic test for Plasmodium vivax, to determine a likelihood of a specific timing of infection by P. vivax in a subject, and hence identify individuals with a high probability of being infected with oth...
|
|
WO/2018/130506A1 |
In the detection of the presence of a biomarker or the like in a sample of a flowable substance, e.g. a powder or a liquid, usually a body fluid, such as blood, urine, or saliva, for example, a disposable sample receiver (3) is used, whi...
|
|
WO/2018/130988A1 |
The present invention provides cryptates derivatives of formula (I) and conjugates thereof with excellent fluorescent properties. The cryptates are useful in biological assays and methods for the detection and identification of various a...
|
|
WO/2018/132062A1 |
This disclosure relates to a multiplex diagnostic method and related kits thereof for detecting the presence of different target analytes in a sample, the method comprising providing the sample and a plurality of reporter particles such ...
|
|
WO/2018/132562A1 |
The present invention is related to compositions comprising clarified limulus amebocyte lysate (LAL), wherein the LAL is substantially free of coagulogen and methods of making such compositions. The invention further relates to a method ...
|
|
WO/2018/131981A2 |
Disclosed are a biosensor having an RF bandpass structure, a method for sensing biometric data using the same, and a method for manufacturing an RF biosensor having a metal line and an air-bridge structure. The RF biosensor consisting of...
|
|
WO/2018/130590A1 |
The invention relates to a device and to a method for detecting blood or a blood constituent or determining the concentration of blood or of a blood constituent in a liquid, in particular for detecting hemoglobin in a dialysis liquid. Th...
|
|
WO/2018/130676A1 |
The present invention is in the field of coagulation diagnosis and relates to a universal control material and its production and use for quality control of coagulation factor inhibitor tests.
|
|
WO/2018/132400A1 |
The present disclosure provides methods for non-invasive prenatal screening (NIPS) of fetal aneuploidies. The present methods are based on analyzing cell-free fetal DNA (cff DNA) found in a pregnant woman's circulation through the next g...
|
|
WO/2018/132680A1 |
The invention is directed to a method for rapidly determining antibiotic susceptibility in bodily fluid samples based on rigorous multidimensional statistical metrics. In some embodiments, the method incorporates flow cytometry to determ...
|
|
WO/2018/130836A1 |
A method of diagnosing or monitoring Mycobacterium avium subspecies paratuberculosis (MAP) infection, which method comprises detecting the presence of the polypeptide (MAP P900) encoded by the positive strand of IS900, or a fragment ther...
|
|
WO/2018/130476A1 |
The present invention pertains to a method for determining the total iron content in a sample comprising Fe3+, comprising the steps of a) combining the sample comprising Fe3+ with an organic reducing agent and a chromogenic compound capa...
|
|
WO/2018/132285A1 |
Aspects of the present disclosure include a titration probe (104) for titrating a whole blood sample, said probe (104) mitigating the occurrences of titration probe clots. A bar (102) such as segment of music wire, is extended across the...
|
|
WO/2018/132746A1 |
Provided herein are methods for early detection of Parkinson's diseases (PD), especially in individuals showing no motor symptoms, by detecting PD-distinct scent using a trained animal (such as a canine). Specific rigorous animal trainin...
|
|
WO/2018/132361A1 |
A method for measuring the radiant exposure of energy curable inks or coatings on a printing press. The steps for measuring comprise: a) providing an ink or coating material comprising a fluorescent probe; b) transferring the ink or coat...
|
|
WO/2018/131590A1 |
This method for producing a nucleic acid array includes: a step in which a positive resist composition including a photoacid generator for generating an acid as a result of being exposed to light, is used to form a resist film on a solid...
|
|
WO/2018/130855A1 |
The invention relates to a method of determining the typhoid status of a subject comprising: a) obtaining a sample provided by a subject; b) screening the sample for the presence of antibodies to the expression product of one or more gen...
|
|
WO/2018/130545A1 |
The present invention relates to a complex comprising at least one lanthanide (Ln) and at least one compound (C) comprising a unit of formula (I), said unit of formula (I) being covalently bound to at least one antenna that absorbs at a ...
|
|
WO/2018/130657A1 |
A therapeutic agent capable of binding to the receptor CLPTM1 at the surface of an immune cell and modulating its activity for use in modulating the activity of the immune system to treat cancer, wherein the therapeutic agent is capable ...
|
|
WO/2018/131186A1 |
A method for detecting residual crosslinking aid in a crosslinked resin molded body, said method for detecting residual crosslinking aid comprising a subject heating step in which a crosslinked resin molded body is heated for a time of 3...
|
|
WO/2018/131829A1 |
Problem: There is a problem that skin cells cultured in a static state cannot imitate a stretching environment faced by real skin. Solution: The present invention relates to a skin-on-a-chip, and can provide a skin-on-a-chip which is mor...
|
|
WO/2018/132022A1 |
The object of the invention is a device for detecting and/or determining the concentration of an analyte present in a tissue, comprising a sensor which is an optical fibre interferometer, one interferometer arm being coated with an immob...
|
|
WO/2018/130405A1 |
The invention concerns a method and a system for diagnosing a pathology in a mammal in need thereof. The method according to the invention comprises the following steps: collecting a blood, blood plasma or blood serum sample from said ma...
|
|
WO/2018/132571A1 |
This document relates to materials and methods involved in treating cancer. For example, materials and methods for using one or more oncolytic viruses (e.g., one or more oncolytic viruses) to treat cancer in a mammal (e.g., a human) iden...
|
|
WO/2018/130570A1 |
The invention relates to a sensor device (1) for detecting a gas (G), particularly a permanent gas such as H2, CO, CO2, CH4, comprising: an adsorption filter (30) comprising a body (2) consisting of a molecular sieve material, a sensing ...
|
|
WO/2018/132685A1 |
Disclosed herein are methods and devices for a cell-free assay platform that enables measurement of membrane protein function by measuring the events that are induced by ligand binding or other stimuli.
|
|
WO/2018/130170A1 |
A high-affinity peptide for a tumor necrosis factor alpha. Amino acid sequences of the peptide are as represented by SEQ.ID.NO.1 and SEQ.ID.NO.3 or are tandem or branched peptide molecular sequences with a single repeat or multiple repea...
|
|
WO/2018/132639A1 |
The invention provides methods of diagnosing ocular cicatricial pemphigoid (OCP) in a subject, by determining the level or concentration of autoantibodies that bind β4 integrin in a biological sample obtained from the subject. In embodi...
|
